This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Swiss Institute for Pulmonary Research | |
|---|---|
| Name | Swiss Institute for Pulmonary Research |
| Formation | 1998 |
| Type | Research institute |
| Location | Zurich, Switzerland |
| Leader title | Director |
| Leader name | Dr. Markus Keller |
| Staff | 220 |
Swiss Institute for Pulmonary Research is a biomedical research institute based in Zurich, Switzerland, dedicated to lung science, respiratory medicine, and translational pulmonary care. It integrates basic science, clinical investigation, and population health through interdisciplinary teams drawn from universities, hospitals, and research centers. The institute engages with international organizations and professional societies to influence policy, clinical guidelines, and therapeutic development.
Founded in 1998 following a consortium agreement between the University of Zurich and the University Hospital Zurich, the institute emerged during a period of expansion in European biomedical research funding exemplified by the European Research Area and the Framework Programmes. Early strategic partnerships included collaborations with the European Respiratory Society, the Swiss National Science Foundation, and the Wellcome Trust, mirroring contemporaneous alliances among institutions such as the Karolinska Institutet, Max Planck Society, and Imperial College London. Throughout the 2000s the institute expanded its remit through grants from the Horizon 2020 programme and strategic alliances with industry partners like Roche, Novartis, and AstraZeneca. Milestones included launching cohort studies influenced by designs used by the Framingham Heart Study, the Copenhagen City Heart Study, and the British Lung Foundation initiatives. Leadership transitions involved directors with prior appointments at institutions such as the University of Cambridge, Johns Hopkins University, Harvard Medical School, and the University of Toronto. The institute’s history intersects with multicenter trials and networks including the Global Initiative for Chronic Obstructive Lung Disease, the World Health Organization, and the European Centre for Disease Prevention and Control.
Governance follows a board model with representation from the Swiss Federal Institutes of Technology, cantonal health authorities, philanthropic foundations such as the Wellcome Trust and the Gates Foundation, and academic partners including ETH Zurich, University of Geneva, and University of Basel. An executive committee reports to advisory boards comprising members from institutions like Massachusetts General Hospital, Mayo Clinic, Karolinska Institutet, Institut Pasteur, and the National Institutes of Health. Internal departments mirror structures at research organizations such as the Francis Crick Institute and the Broad Institute, with divisions in basic biology, clinical trials, epidemiology, and bioinformatics. Regulatory compliance aligns with Swissmedic, the European Medicines Agency, and the International Council for Harmonisation, while ethical oversight engages institutional review boards similar to those at Columbia University and Stanford University.
Primary programs address pathophysiology, epidemiology, and therapeutics for airway diseases, interstitial lung diseases, pulmonary vascular diseases, and infection. Investigative themes include molecular mechanisms studied with techniques pioneered at Cold Spring Harbor Laboratory and the Salk Institute, translational immunology influenced by the work at Rockefeller University, and translational genomics drawing on methods from the Broad Institute and EMBL. Programs span asthma, chronic obstructive pulmonary disease, cystic fibrosis, idiopathic pulmonary fibrosis, pulmonary hypertension, acute respiratory distress syndrome, and emerging infectious diseases such as influenza and coronaviruses. Research modalities integrate single-cell sequencing approaches developed at the Wellcome Sanger Institute, CRISPR screens inspired by the Zhang lab at MIT, proteomics methods from the Max Planck Institute of Biochemistry, and imaging techniques used at the European Molecular Biology Laboratory. The institute maintains disease registries modeled after registries at the European Lung Foundation and collaborates on randomized controlled trials similar to those conducted by the National Heart, Lung, and Blood Institute.
Clinical translation occurs through partnerships with University Hospital Zurich, Inselspital Bern, Geneva University Hospitals, and regional cantonal hospitals. Trials and interventional studies follow frameworks from CONSORT and involve sponsors such as GlaxoSmithKline and Pfizer in selected programs. Clinical programs include pulmonary rehabilitation clinics inspired by protocols from the American Thoracic Society and ERS, specialized interventional pulmonology services using technologies akin to those at Cleveland Clinic and Royal Brompton Hospital, and precision-medicine initiatives paralleling programs at Dana-Farber Cancer Institute. The institute contributes to guideline development with professional societies like the European Respiratory Society, American Thoracic Society, and International Society for Heart and Lung Transplantation, and participates in multicenter networks including ISARIC and the International Severe Acute Respiratory and Emerging Infection Consortium.
Core facilities include genomics and sequencing platforms comparable to those at the Broad Institute and EMBL-EBI, advanced imaging suites inspired by the Allen Institute and the Max Planck Institute for Biophysical Chemistry, a Biosafety Level 3 laboratory meeting standards used by the Pasteur Institute and the NIH, and a clinical trials unit accredited in line with units at the Oxford Clinical Trials Research Unit. Biobanks follow standards from BBMRI-ERIC and house samples analogous to cohorts like UK Biobank and the National Biobank of Singapore. Computational resources leverage high-performance clusters and cloud collaborations with providers used by CERN and the European Grid Infrastructure, supporting bioinformatics pipelines similar to those at the European Bioinformatics Institute.
International collaborations include partnerships with University College London, Charité – Universitätsmedizin Berlin, Institut Pasteur, Karolinska Institutet, University of California San Francisco, and the University of Pennsylvania. Industry partnerships extend to biotechnology firms such as Genentech, Vertex Pharmaceuticals, and Regeneron, and diagnostics collaborations mirror efforts by Abbott Laboratories and Siemens Healthineers. Public health linkages involve the World Health Organization, European Centre for Disease Prevention and Control, and Swiss Federal Office of Public Health. Research consortia include participation in networks like the Human Cell Atlas, the LungMAP initiative, and the European Respiratory Society clinical research collaborations.
Training programs span doctoral fellowships in collaboration with ETH Zurich, postdoctoral fellowships modeled on Marie Skłodowska-Curie Actions, clinical fellowship rotations with University Hospital Zurich and Inselspital Bern, and short courses that parallel offerings from Cold Spring Harbor Laboratory and EMBL. Continuing medical education activities are conducted with academic partners similar to Harvard Medical School and the University of Oxford, while summer schools and workshops invite speakers from institutions such as Yale School of Medicine, Duke University, and Kyoto University. The institute also hosts visiting scholars from institutions including Princeton University, McGill University, and the University of Melbourne, and contributes to professional accreditation through cooperation with the European Respiratory Society and American Board of Internal Medicine.
Category:Medical research institutes in Switzerland